Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Peripheral T-cell Lymphoma

NCT01947140 is registered in ClinicalTrials.gov with Jennifer Amengual as lead sponsor.

NCT NCT01947140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01947140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/IIA Study of the Novel Antifolate Agent Pralatrexate in Combination With the Histone Deacetylase Inhibitor Romidepsin for the Treatment of Patients With Peripheral T-cell Lymphoma
Lead sponsor
Jennifer Amengual
Phase
Phase 1/2
Overall status
Terminated
Start date
September 9, 2013
Completion date
September 1, 2022
Enrollment
57 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hodgkin lymphoma, lymphoid malignancies, lymphoma, multiple myeloma, non-hodgkin lymphoma